A
Aktis Oncology
Biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals
About Aktis Oncology
Aktis Oncology is a pioneering biotech company focused on developing novel radiotherapies for cancer patients with unmet medical needs. Operating in the oncology market, Aktis targets a broad set of commonly occurring cancers, aiming to revolutionize cancer treatment by putting solid tumors into remission. The company serves patients who have limited treatment options, providing them with innovative therapeutic solutions.
Aktis Oncology's business model revolves around the research, development, and commercialization of transformative cancer therapies. The company generates revenue through the development and licensing of its proprietary radiotherapy molecules, as well as potential partnerships with pharmaceutical companies. By focusing on groundbreaking science and clinical development, Aktis aims to bring new hope to cancer patients worldwide.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2026
Open roles
Aktis Oncology in the Boston ecosystem
The Aktis Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A14 investors entered at this stage
MPM BioImpact
EcoR1 Capital
Vida Ventures
Novartis
Bristol-Myers Squibb
Octagon Capital Partners
TCGX
MRL Ventures
ArrowMark Partners- TCTimefolio Capital
Eli Lilly
RA Capital Management
RTW InvestmentsJanus Henderson Investors
Series B and later1 investor entered at this stage
Avidity Partners
Source: Dealroom Talent Intelligence.
Patents
5 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Aktis Oncology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Z-Alpha pulls in $7.48M round as global pharma joins alpha-therapy bet

